A Pilot Study of Fecal Microbiome and Neutrophil Cellular Adhesion Molecules in Patients With Sickle Cell Disease (SCD)
NCT03007849 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2017-01-04
Summary
Patients with sickle cell disease often develop painful crisis without any obvious reasons. Some patients are more likely to develop this complication than others. It is now clear that painful crisis only occurs when sickled red blood cells stick to white blood cells that have been activated, usually by inflammation or infections. A recent study in mice with sickle cell disease showed that the use of long term antibiotics could reduce the number of activated white blood cells and reduce death of the mice during sickle cell crisis.
The investigators believe that sickle cell patients who develop frequent painful crisis may have a different pattern of bacteria in their intestine when compared to those whose painful crisis occurs infrequently. In this study, the investigators propose to study sickle cell subject's blood to determine how many activated white blood cells he/she have. The investigators will also examine his/her stool to compare the bacteria in his/her stool to those other sickle cell patients. The investigators will then investigate whether or not the results from the blood and stool tests correlate with how frequently the patient develops painful crisis.
The investigators will examine the patients' medical records to find out how many times they have been admitted to the hospital for sickle cell crisis in the last 12 months. The investigators will also obtain information on the following: their age, their sex, whether they are taking hydroxyurea or Penicillin, when they last had a transfusion or exchange transfusion therapy and painful crisis needing hospital admission, whether they have received any antibiotics (other than Penicillin) in the last 4 weeks, and whether they are experiencing a painful crisis at the time that they enter the study. The investigators will obtain, from their previous laboratory results, their levels of hemoglobin F and markers of inflammation. The investigators will check their hemoglobin F level if they have not already had this tested.
The investigators expect to enroll 50 subjects into this study at Rhode Island Hospital/Hasbro Children's Hospital.
Conditions
Sponsors & Collaborators
-
Rhode Island Hospital
lead OTHER
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-31
- Primary Completion
- 2017-12-31
- Completion
- 2017-12-31
More Related Trials
-
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
NCT05348915 ·Status: TERMINATED ·Phase: PHASE3
-
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
NCT00005300 ·Status: COMPLETED
-
Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization
NCT03405402 ·Status: COMPLETED ·Phase: NA
-
Blood Flow and Pain Crises in People With Sickle Cell Disease
NCT01568710 ·Status: COMPLETED
-
Genetics and Pain Severity in Sickle Cell Disease
NCT01441141 ·Status: COMPLETED
-
Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease
NCT00252122 ·Status: TERMINATED ·Phase: PHASE4
-
Risk Factors for Allo-immunization in Sickle Cell Disease
NCT03401125 ·Status: WITHDRAWN
-
Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging
NCT03478917 ·Status: COMPLETED
-
Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease
NCT00600665 ·Status: COMPLETED ·Phase: NA
-
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
NCT02620488 ·Status: COMPLETED ·Phase: NA
-
Dense Red Blood Cells in Sickle Cell Children
NCT02887118 ·Status: TERMINATED
-
COVID-19 Vaccine Response in Sickle Cell Disease
NCT05139992 ·Status: COMPLETED
-
Acute Kidney Injury in Patients With Sickle Cell Disease
NCT03105271 ·Status: COMPLETED
-
Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient
NCT06986837 ·Status: COMPLETED
-
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
NCT03132324 ·Status: TERMINATED ·Phase: PHASE1
-
Neutrophil Extracellular Traps and Sickle Cell Disease
NCT02004808 ·Status: UNKNOWN
-
Predictors of Pain in Sickle Cell Disease
NCT06139510 ·Status: RECRUITING ·Phase: NA
-
Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Sickle Cell Disease
NCT04877054 ·Status: COMPLETED ·Phase: NA
-
Study of Blood Platelets in Sickle Cell Disease
NCT00226083 ·Status: WITHDRAWN
-
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
NCT03805581 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
NCT05791591 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Carbon Monoxide Levels and Sickle Cell Disease Severity
NCT01547793 ·Status: COMPLETED
-
N-Acetylcysteine in Patients With Sickle Cell Disease
NCT01849016 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
NCT04610866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
NCT06944067 ·Status: RECRUITING